StocksMedium•2 October 2026•
1 min read
FDA Extends Review of Novo Nordisk Hemophilia Drug Over Facility Issues
Key Facts
1The US FDA has extended its review of Novo Nordisk's experimental hemophilia A drug.
2The delay is attributed to ongoing remediation work at a manufacturing facility owned by the Danish drugmaker.
The US Food and Drug Administration (FDA) has extended its review period for an experimental hemophilia A drug developed by Novo Nordisk. Reuters reported that the delay is attributed to ongoing remediation work at a manufacturing facility owned by the Danish drugmaker.
The regulatory extension is focused on ensuring production sites meet safety and compliance standards rather than clinical failures of the treatment itself. The delay shifts the timeline for the potential market entry of the new therapy while the company addresses the facility issues.